Tags : SB15

Biosimilars

Samsung Bioepis Reports the Initiation of P-III Study for SB15

Shots: The P-III study will compare the efficacy, safety, PK, and immunogenicity between SB15 and Eylea in 446 patients with neovascular age-related macular degeneration The company has two ophthalmology biosimilar candidates in clinical development, SB11 (ranibizumab) and SB15 (aflibercept). On May 18, 2020, Samsung Bioepis reports 24-week interim results from a P-III study of SB11 […]Read More